UY32769A - Composición para el tratamiento de la hiperplasia prostática benigna - Google Patents

Composición para el tratamiento de la hiperplasia prostática benigna

Info

Publication number
UY32769A
UY32769A UY0001032769A UY32769A UY32769A UY 32769 A UY32769 A UY 32769A UY 0001032769 A UY0001032769 A UY 0001032769A UY 32769 A UY32769 A UY 32769A UY 32769 A UY32769 A UY 32769A
Authority
UY
Uruguay
Prior art keywords
treatment
composition
benign prostate
prostate hyperplasia
hyperplasia
Prior art date
Application number
UY0001032769A
Other languages
English (en)
Inventor
Axel Niclas Petri
Erichsen Lars
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of UY32769A publication Critical patent/UY32769A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

Composiciones que comprenden degarelix para el tratamiento de la hiperplasia prostática benigna (HPB)
UY0001032769A 2009-07-06 2010-07-07 Composición para el tratamiento de la hiperplasia prostática benigna UY32769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09251738 2009-07-06
US23581609P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
UY32769A true UY32769A (es) 2011-02-28

Family

ID=41112615

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032769A UY32769A (es) 2009-07-06 2010-07-07 Composición para el tratamiento de la hiperplasia prostática benigna

Country Status (18)

Country Link
US (2) US20110039787A1 (es)
EP (1) EP2451469B1 (es)
JP (1) JP2012532188A (es)
KR (1) KR20120038956A (es)
CN (1) CN102470159A (es)
AR (1) AR081439A1 (es)
AU (1) AU2010269958A1 (es)
BR (1) BR112012000185A2 (es)
CA (1) CA2766008A1 (es)
IL (1) IL216987A0 (es)
MX (1) MX2012000315A (es)
NZ (1) NZ597060A (es)
RU (1) RU2011152514A (es)
SA (1) SA110310575B1 (es)
TW (1) TW201105344A (es)
UY (1) UY32769A (es)
WO (1) WO2011004260A2 (es)
ZA (1) ZA201109513B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
ES2617336T3 (es) 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
WO2013178788A2 (en) * 2012-06-01 2013-12-05 Ferring B.V. Manufacture of degarelix
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JP2719233B2 (ja) * 1991-04-25 1998-02-25 デゲンギ，ロマノ 黄体形成ホルモン放出ホルモン拮抗ペプチド
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
EP2257324B1 (en) * 2008-02-11 2016-07-27 Safety Syringes, Inc. Syringe with safety needle guard and clip to prevent release of guard during reconstitution process
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
ES2617336T3 (es) * 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
PL2731607T3 (pl) * 2011-07-15 2018-03-30 Ferring B.V. Sposób koordynacji czasu kolonoskopii, w którym podaje się kompozycję pikosiarczanową

Also Published As

Publication number Publication date
SA110310575B1 (ar) 2014-10-23
WO2011004260A2 (en) 2011-01-13
MX2012000315A (es) 2012-02-13
RU2011152514A (ru) 2013-08-20
KR20120038956A (ko) 2012-04-24
NZ597060A (en) 2013-05-31
JP2012532188A (ja) 2012-12-13
TW201105344A (en) 2011-02-16
CA2766008A1 (en) 2011-01-13
BR112012000185A2 (pt) 2017-06-13
US20120172302A1 (en) 2012-07-05
WO2011004260A3 (en) 2011-05-19
ZA201109513B (en) 2012-09-26
CN102470159A (zh) 2012-05-23
EP2451469A2 (en) 2012-05-16
AR081439A1 (es) 2012-09-05
US20110039787A1 (en) 2011-02-17
AU2010269958A1 (en) 2012-01-19
IL216987A0 (en) 2012-02-29
EP2451469B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
UY32769A (es) Composición para el tratamiento de la hiperplasia prostática benigna
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
NZ622505A (en) Therapeutic compounds and compositions
CL2012000302A1 (es) Compuestos derivados de tubulisinas; compuestos conjugados que los comprenden; compuestos intermediarios; y uso para tratar el cancer.
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
GT200900027A (es) Compuestos organicos
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
ECSP11010787A (es) Compuestos orgánicos
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
BRPI0908127A2 (pt) Método para o tratamento do câncer da próstata com degarelix antagonista do gnrh
CR11629A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA- DESATURASA.
MX2013007268A (es) Activadores de pkm2 bicíclicos.
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
ECSP077247A (es) Trans - clomifeno para el tratamiento de la hipertrofia prostatica benigna, cancer prostatico, hipogonodismo, trigliceridos elevados y alto colesterol
BR112012011823A2 (pt) métodos e composições para tratar tumores sólidos e outras malignidades
IL207682A0 (en) Compositions for the treatment of benign prostate hypertrophy, prostatitis, prostatosis and prostate cancer
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
ECSP12011837A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
EA201100882A1 (ru) Профилактическое/терапевтическое средство против рака

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190211